112 related articles for article (PubMed ID: 17127227)
1. Impact of carbapenem administration on systemic endotoxemia in patients with severe sepsis and Gram-negative bacteremia.
Giamarellos-Bourboulis EJ; Mega A; Pavleas I; Archontoulis N; Rigas K; Vernikos P; Giamarellou H; Thomopoulos G
J Chemother; 2006 Oct; 18(5):502-6. PubMed ID: 17127227
[TBL] [Abstract][Full Text] [Related]
2. Impact of the introduction of real-time therapeutic drug monitoring on empirical doses of carbapenems in critically ill burn patients.
Fournier A; Eggimann P; Pagani JL; Revelly JP; Decosterd LA; Marchetti O; Pannatier A; Voirol P; Que YA
Burns; 2015 Aug; 41(5):956-68. PubMed ID: 25678084
[TBL] [Abstract][Full Text] [Related]
3. Meropenem versus imipenem/cilastatin in the treatment of sepsis in Chinese patients.
Kuo BI; Fung CP; Liu CY
Zhonghua Yi Xue Za Zhi (Taipei); 2000 May; 63(5):361-7. PubMed ID: 10862445
[TBL] [Abstract][Full Text] [Related]
4. The level of endotoxemia in sepsis varies in relation to the underlying infection: Impact on final outcome.
Kritselis I; Tzanetakou V; Adamis G; Anthopoulos G; Antoniadou E; Bristianou M; Kotanidou A; Lignos M; Polyzos K; Retsas T; Sassopoulou P; Papaioannou AI; Sinapidis D; Sereti K; Vittoros V; Ghanas P; Gogos C; Giamarellos-Bourboulis EJ
Immunol Lett; 2013 May; 152(2):167-72. PubMed ID: 23747516
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness model of empiric doripenem compared with imipenem-cilastatin in ventilator-associated pneumonia.
Zilberberg MD; Mody SH; Chen J; Shorr AF
Surg Infect (Larchmt); 2010 Oct; 11(5):409-17. PubMed ID: 20666580
[TBL] [Abstract][Full Text] [Related]
6. [Investigation on administration method of carbapenems].
Mikamo H; Ninomiya M; Tamaya T
Jpn J Antibiot; 2002 Dec; 55(6):875-81. PubMed ID: 12621741
[TBL] [Abstract][Full Text] [Related]
7. Doripenem: excess mortality.
Prescrire Int; 2012 Sep; 21(130):214. PubMed ID: 23016255
[No Abstract] [Full Text] [Related]
8. Circulating endotoxin during initial antibiotic treatment of severe gram-negative bacteremic infections.
Maury E; Barakett V; Blanchard H; Guitton C; Fitting C; Vassal T; Chauvin P; Guidet B; Offenstadt G
J Infect Dis; 1998 Jul; 178(1):270-3. PubMed ID: 9652453
[TBL] [Abstract][Full Text] [Related]
9. Carbapenem therapy for bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli or Klebsiella pneumoniae.
Lee NY; Huang WH; Tsui KC; Hsueh PR; Ko WC
Diagn Microbiol Infect Dis; 2011 May; 70(1):150-3. PubMed ID: 21398070
[TBL] [Abstract][Full Text] [Related]
10. Comparative evaluation of intratracheal colistimethate sodium, imipenem, and meropenem in BALB/c mice with carbapenem-resistant Acinetobacter baumannii pneumonia.
Tang HJ; Chuang YC; Ko WC; Chen CC; Shieh JM; Chen CH; Lee NY; Chiang SR
Int J Infect Dis; 2012 Jan; 16(1):e34-40. PubMed ID: 22088863
[TBL] [Abstract][Full Text] [Related]
11. [A preliminary study of the administration of carbapenem antibiotics in sepsis patients on the basis of the administration time].
Kojika M; Sato N; Hakozaki M; Suzuki Y; Takahasi G; Endo S; Suzuki K; Wakabayasi G
Jpn J Antibiot; 2005 Oct; 58(5):452-7. PubMed ID: 16379157
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized study.
Chastre J; Wunderink R; Prokocimer P; Lee M; Kaniga K; Friedland I
Crit Care Med; 2008 Apr; 36(4):1089-96. PubMed ID: 18379232
[TBL] [Abstract][Full Text] [Related]
13. The impact of an antibiotic cycling program on empirical therapy for gram-negative infections.
Merz LR; Warren DK; Kollef MH; Fridkin SK; Fraser VJ
Chest; 2006 Dec; 130(6):1672-8. PubMed ID: 17166981
[TBL] [Abstract][Full Text] [Related]
14. Pharmacodynamic profiling of doripenem, imipenem and meropenem against prevalent Gram-negative organisms in the Asia-Pacific region.
Kiratisin P; Keel RA; Nicolau DP
Int J Antimicrob Agents; 2013 Jan; 41(1):47-51. PubMed ID: 23127484
[TBL] [Abstract][Full Text] [Related]
15. Ceftazidime- and imipenem-induced endotoxin release during treatment of gram-negative infections.
Byl B; Clevenbergh P; Kentos A; Jacobs F; Marchant A; Vincent JL; Thys JP
Eur J Clin Microbiol Infect Dis; 2001 Nov; 20(11):804-7. PubMed ID: 11783697
[TBL] [Abstract][Full Text] [Related]
16. Resistance to empiric antimicrobial treatment predicts outcome in severe sepsis associated with Gram-negative bacteremia.
Micek ST; Welch EC; Khan J; Pervez M; Doherty JA; Reichley RM; Hoppe-Bauer J; Dunne WM; Kollef MH
J Hosp Med; 2011 Sep; 6(7):405-10. PubMed ID: 21916003
[TBL] [Abstract][Full Text] [Related]
17. Using local clinical and microbiological data to develop an institution specific carbapenem-sparing strategy in sepsis: a nested case-control study.
Lambregts MMC; Hendriks BJC; Visser LG; Bernards ST; de Boer MGJ
Antimicrob Resist Infect Control; 2019; 8():19. PubMed ID: 30701071
[TBL] [Abstract][Full Text] [Related]
18. Impact of imipenem and amikacin pharmacokinetic/pharmacodynamic parameters on microbiological outcome of Gram-negative bacilli ventilator-associated pneumonia.
Pajot O; Burdet C; Couffignal C; Massias L; Armand-Lefevre L; Foucrier A; Da Silva D; Lasocki S; Laouénan C; Mentec H; Mentré F; Wolff M
J Antimicrob Chemother; 2015 May; 70(5):1487-94. PubMed ID: 25630642
[TBL] [Abstract][Full Text] [Related]
19. [Changes in plasma levels of LPS, TNFalpha and IL-6 in burn patients with severe infection treated with Imipenem or Cefoperazone].
Wang HM; Cao WF; Peng YZ; Xiao GX; Yang XY
Zhonghua Shao Shang Za Zhi; 2004 Apr; 20(2):95-7. PubMed ID: 15312472
[TBL] [Abstract][Full Text] [Related]
20. Third generation cephalosporin resistant Enterobacteriaceae and multidrug resistant gram-negative bacteria causing bacteremia in febrile neutropenia adult cancer patients in Lebanon, broad spectrum antibiotics use as a major risk factor, and correlation with poor prognosis.
Moghnieh R; Estaitieh N; Mugharbil A; Jisr T; Abdallah DI; Ziade F; Sinno L; Ibrahim A
Front Cell Infect Microbiol; 2015; 5():11. PubMed ID: 25729741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
